Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 16/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 7/20 | 0.53 |
| ▸ | IKBKB | O14920 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584094 | 0.88 | JAK2 (0.59) | JAK2ACVR1JAK3HDAC3NCOR1 | |
| SCHEMBL4830383 | 0.88 | JAK2 (0.53) | JAK2JAK3HDAC3NCOR1JAK1 | |
| SCHEMBL4385536 | 0.86 | JAK2 (0.73) | GSK3BJAK2ACVR1JAK3JAK1 | |
| SCHEMBL4583408 | 0.86 | JAK2 (0.57) | JAK2ACVR1JAK3IKBKBHDAC3 | |
| SCHEMBL3759170 | 0.82 | MAPK8 (0.71) | GSK3BJAK2JAK3IKBKBHDAC1 | |
| SCHEMBL4584356 | 0.82 | JAK2 (0.52) | JAK2JAK3HDAC1HDAC6 | |
| SCHEMBL4381182 | 0.81 | JAK2 (0.60) | JAK2ACVR1JAK3HDAC3NCOR1 | |
| SCHEMBL4383888 | 0.81 | MEN1 (0.68) | JAK2JAK3IKBKBJAK1TYK2 | |
| SCHEMBL4828753 | 0.80 | JAK2 (0.55) | GSK3BJAK2JAK3TYK2HDAC1 | |
| SCHEMBL4379827 | 0.80 | JAK2 (0.70) | JAK2JAK3JAK1TYK2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |